Jan Wald
Jan Wald
acid might passed test
They might have passed the acid test of being too big.
earnings interest investor renew report
There was nothing in the earnings report that would renew investor interest.
easily
I think they easily could go up to $76 without a lot of damage.
johnson stronger threat
The combination of Guidant and Johnson & Johnson is a stronger threat to Medtronic,
boston buying good insider investors scientific
I think investors do take insider buying as a good sign, and I think they especially wanted Boston Scientific to do it.
bent
It underscores why they were so bent on doing the Guidant deal.
hurting
I think of all the pieces, it's pharmaceuticals that are hurting them the most.
time
But that is an awfully long time to look out for pharmaceuticals.
boston heard scientific single
I haven't heard from a single Guidant shareholder who doesn't like the Boston Scientific deal.
actions louder speak
This is one of those times when actions speak louder than words.
accused answer both devices medical
In investors' minds, they've been accused of being a one-trick pony, and they don't have a pipeline. If they get Guidant, they answer both those questions. They'll be in one of the fastest-growing medical devices markets, for implantable defibrillators, and they'll have Guidant's pipeline.
accept board boston clearing price scientific terms
The price wasn't as important as clearing up some terms and conditions. If Boston Scientific has done that, then I don't know why Guidant's board wouldn't accept this bid.